Showing results (391-400 of 582) with videos related to

Sort By:
Pageof 59
Biochimie|January 1, 1991
Gene regulation by interleukin 6G H Fey, M Hattori, G Hocke, et al.
The Journal of Biological Chemistry|June 20, 2000
Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinaseF Blanchard, L Duplomb, Y Wang, et al.
Annals of the New York Academy of Sciences|July 21, 1995
Interleukin-6-type cytokines and their receptors for gene therapy of melanomaA Mackiewicz, M Wiznerowicz, E Roeb, et al.
Psychopharmacology|May 17, 2025
Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J miceShelby A McGriff, Jacquelin C Hecker, Alexander D Maitland, et al.
Synapse (New York, N.Y.)|February 5, 2000
Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuseR B Rothman, J S Partilla, M H Baumann, et al.
Addiction Biology|January 7, 2016
Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ9 -tetrahydrocannabinolAlexander F Hoffman, Matthew D Lycas, Jakub R Kaczmarzyk, et al.
Annals of the New York Academy of Sciences|July 10, 2002
Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependenceMichael H Baumann, Jennifer M Phillips, Mario A Ayestas, et al.
Psychopharmacology|September 3, 2020
The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male ratsSimon D Brandt, Hailey M Walters, John S Partilla, et al.
Annals of the New York Academy of Sciences|November 21, 2000
Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addictionR B Rothman, J S Partilla, C M Dersch, et al.
Circulation|March 1, 1990
Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarctionC Bode, G Schuler, T Nordt, et al.
Pageof 59